Pharmaceuticals

Neutralizing Antibody Market Outlook Showing Demand Growth Across 2026–2030

March 23, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Increase Is Anticipated For The Neutralizing Antibody Market Over The 2026–2030 Period?

The neutralizing antibody market has experienced swift expansion recently. Its size is projected to increase from $257.81 billion in 2025 to $288.51 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 11.9%. Historically, this expansion has been driven by factors such as the emergence of viral outbreaks like sars-cov-2, the advancement of early monoclonal antibody platforms, augmented research and development (R&D) in immunology, the integration of antibodies into diagnostic assays, and the dependence on animal-derived polyclonal antibodies.

The neutralizing antibody market is poised for substantial growth over the next few years, with projections indicating it will reach $447.16 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.6%. This expansion during the forecast period is attributed to several factors: advancements in fully human and humanized monoclonal antibodies, the progress in recombinant polyclonal antibody technology, a surging global demand for covid-19 and influenza therapeutics, increased collaborations between pharmaceutical and biotech companies, and the expansion of antibody research into emerging markets. Significant trends anticipated for this period include rising investment in neutralizing antibody therapeutics, the broadened development of monoclonal and polyclonal antibodies, increasing applications in viral diagnostics and research, a heightened focus on personalized medicine and targeted therapies, and enhanced regulatory oversight and compliance for antibody production.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24620&type=smp

Which Economic Or Industry Drivers Are Impacting The Neutralizing Antibody Market?

The increasing occurrence of infectious diseases is anticipated to boost the expansion of the neutralizing antibody market moving forward. These diseases are defined as ailments resulting from detrimental microorganisms like bacteria, viruses, fungi, or parasites, capable of transmission directly or indirectly between individuals. The growing frequency of infectious diseases stems from greater travel, which aids in the swift international spread of pathogens. Neutralizing antibodies improve the treatment of infectious diseases by precisely identifying and neutralizing pathogens, thus proving effective in hindering disease advancement. They better patient results by offering accurate and prompt immune defense. For example, in February 2024, the UK Health Security Agency, a government body in the UK, reported that tuberculosis, a contagious bacterial infection primarily affecting the lungs, saw cases in England rise to 4,850 in 2023, an increase of 10.7% from 4,380 cases in 2022. Consequently, the increasing prevalence of infectious diseases is a key factor propelling the growth of the neutralizing antibody market.

How Is The Neutralizing Antibody Market Segmented Across Key Categories?

The neutralizing antibody market covered in this report is segmented –

1) By Antibody Type: Monoclonal Antibodies, Polyclonal Antibodies

2) By Target Virus: SARS-CoV-2 (COVID-19), Human Immunodeficiency Viruses (HIV), Influenza, Ebola, Zika, Hepatitis C, Other Target Viruses

3) By Distribution Channel: Direct Sales To End-Users, Distributors, Online Retail, Other Distribution Channels

4) By Application: Therapeutics, Diagnostics, Research And Development

5) By End User: Hospitals And Clinics, Research Institutes, Diagnostic Laboratories, Pharmaceutical Companies, Other End Users

Subsegments:

1) By Monoclonal Antibodies: Fully Human Monoclonal Antibodies, Humanized Monoclonal Antibodies, Chimeric Monoclonal Antibodies, Murine Monoclonal Antibodies

2) By Polyclonal Antibodies: Animal-Derived Polyclonal Antibodies, Recombinant Polyclonal Antibodies, Human Polyclonal Antibody Preparations

Which Upcoming Trends Are Expected To Influence The Neutralizing Antibody Market?

Key companies within the neutralizing antibody market are prioritizing the development of advanced solutions, namely, long-acting monoclonal neutralizing antibodies. These are designed to deliver sustained protection against infectious diseases, fulfill unmet medical needs among vulnerable populations, and surmount the constraints of conventional vaccines. These long-acting monoclonal neutralizing antibodies are engineered proteins designed to specifically bind viral antigens with high affinity, thereby blocking infection, while targeted modifications in their Fc region prolong their systemic half-life. Unlike conventional small-molecule antivirals or vaccines, these antibodies provide passive immunity, eliminating the need for repeated dosing or an active immune response. An example is Merck & Co. Inc, a US-based pharmaceutical company, which introduced clesrovimab-cfor in June 2025. This long-acting monoclonal neutralizing antibody received approval from the U.S. FDA. It is a fully human IgG1? antibody specifically targeting the fusion (F) protein of respiratory syncytial virus (RSV). This antibody incorporates a triple amino acid substitution in its Fc region, designed to boost binding to the neonatal Fc receptor and extend its serum half-life. Administered as a single 105 mg intramuscular dose, irrespective of infant weight, it offers season-long protection against RSV, thereby bolstering preventive care for infants and high-risk populations.

Who Are The Dominant Players Shaping The Neutralizing Antibody Market Landscape?

Major companies operating in the neutralizing antibody market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AstraZeneca PLC, Sanofi SA, GlaxoSmithKline plc, Eli Lilly and Company, Regeneron Pharmaceuticals Inc., GeNext Genomics, Celltrion Healthcare Co. Ltd, BeiGene Ltd, AbCellera Biologics Inc., BMC Pharmacology and Toxicology, Anthos Therapeutics, Immunome Inc., Sorrento Therapeutics Inc., Tonix Pharmaceuticals, Abwiz Bio, AXIM Biotechnologies.

Read the full neutralizing antibody market report here:

https://www.thebusinessresearchcompany.com/report/neutralizing-antibody-global-market-report

What Are The Top-Performing Regions Within The Neutralizing Antibody Market?

North America was the largest region in the neutralizing antibody market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neutralizing antibody market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Neutralizing Antibody Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24620&type=smp

Browse Through More Reports Similar to the Global Neutralizing Antibody Market 2026, By The Business Research Company

Immune Health Supplements Market Report 2026

https://www.thebusinessresearchcompany.com/report/immune-health-supplements-global-market-report

Immunoglobulins Market Report 2026

https://www.thebusinessresearchcompany.com/report/immunoglobulins-global-market-report

Antibody Discovery Market Report 2026

https://www.thebusinessresearchcompany.com/report/antibody-discovery-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795